Glenmark Pharma Q1 FY26: Muted Growth, Sharp Drop in Profits

Glenmark Pharmaceuticals, a leading player in the Indian pharma space, posted mixed results for the quarter ended June 2025. Key Highlights: Sales: ₹3,264 Cr — up just 1% YoY, indicating flat revenue momentum despite stable volumes. EBIDT: ₹581 Cr — down 1% YoY, showing mild pressure on operating performance. Net Profit: ₹47 Cr — down 23% YoY, reflecting weaker profitability due to higher costs, possible one-offs, and margin compression. EPS: ₹1.66 vs ₹12.06 last year — a steep 86% YoY decline, pointing to earnings weakness. Analysis : The company managed to hold revenue steady, but sharp erosion in profitability is a red flag. High base effect from last year’s strong quarter, combined with elevated R&D spends and pricing pressure in key geographies, likely impacted margins. With a PE ratio of 43.2, valuations appear expensive relative to current earnings momentum, making near-term upside dependent on margin recovery and stronger international market growth. Disclaimer: This is for informational purposes only and not investment advice.